None of really know the reason(s) but it would be encouraging if we had some Insider buys again..until then, I continue to write naked Apr. 20 puts( took in $3 yesterday) .. $17 if Put not a bad price
Frequently, with emerging bio techs, when the primary drug in the pipeline is approved, the institutions start pricing those stocks based on actual expected earnings rather than the hopes and dreams that have driven the stock price during the past years.
I suspect that is the transition Revance is now going through
News 
Market Data 
Discover 
AI
